Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02602327|
Recruitment Status : Completed
First Posted : November 11, 2015
Last Update Posted : August 1, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Colon Cancer Rectal Cancer Liver Metastases||Drug: Tas-102 Device: SIR-Sphere||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Study of Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases|
|Actual Study Start Date :||January 9, 2017|
|Actual Primary Completion Date :||May 20, 2021|
|Actual Study Completion Date :||August 31, 2021|
Experimental: Tas-102 and radioembolization
Combination therapy with Tas-102 and radioembolization using 90Y resin microspheres
Oral nucleoside antitumor agent consisting of α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 (1H,3H)-pyrimidinedione hydro chloride (TPI) at a molar ratio of 1:0.5.
Other Name: Lonsurf
20-60mm resin microspheres containing Yttrium-90 (90Y, Y90) radioisotope
Other Name: Yttrium-90 (Y90; 90Y) resin microspheres
- Determine dose limiting toxicities (DLT) [ Time Frame: 56 days ]Any adverse events grade ≥ 3 will be reviewed by the treating interventional radiologist and medical oncologist within 24 hours of being informed event. If none of the 3 patients in a cohort experiences a DLT, another 3 patients will be treated at the next higher dose level. However, if 1 of the first 3 patients experiences a DLT, 3 more patients will be treated at the same dose level. The dose escalation will continue until at least 2 patients among a cohort of 3-6 patients experience DLTs (i.e., ≥ 33% of patients with a dose-limiting toxicity at that dose level) or until 3-6 patients had been treated at TAS-102 dose of 35mg/m2 per day in 2 divided doses (up to a maximum of 80 mg per dose) administered concurrently with radioembolization cycles 1 and 2 without experiencing a DLT. DLT window will be 56 days (cycle 1, day 1 to cycle 2, day 28). Dose limiting toxicity will be reached when one of the clinical and/or laboratory parameters are met
- Maximum tolerated dose (MTD) [ Time Frame: Up to 4 years ]Traditional 3+3 design will be used to determine the recommended dose for the dose expansion phase will be defined as the dose level just below this toxic dose level.
- Overall response rate (ORR) [ Time Frame: Up to 4 years ]Radiographic overall response rate (measured in accordance to Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) using imaging. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): 30% decrease in the sum of the longest diameter of target lesionsStable Disease (SD): Small changes that do not meet the criteria for CR, PR, or Progressive Disease (PD): 20% increase in the sum of the longest diameter of target lesions. ORR will be defined as a ratio of the number of patients who demonstrated complete response (CR) or partial response (PR) to the number of all evaluated patients.
- Progression-free survival (PFS) [ Time Frame: Up to 4 years ]PFS will be defined as a time period that started at enrollment, during which a patient neither progressed nor died based on radiographic response.
- Hepatic progression-free survival (HPFS) [ Time Frame: Up to 4 years ]HPFS will be defined as a time period that started at enrollment, during which a patient neither progressed in the liver nor died based on radiographic response.
- Extrahepatic progression free survival (EHPFS) [ Time Frame: Up to 4 years ]EHPFS will be defined as a time period that started at enrollment, during which a patient neither progressed outside the liver nor died based on radiographic response
- Overall survival (OS) [ Time Frame: Up to 12 months ]Overall Survival will be analyzed 12 months after the last patient is enrolled. Overall survival will be assessed using a two-sided, log-rank test. The survival function will be estimated using the Kaplan-Meier product limit method. In addition, two-sided 95% confidence intervals for the median overall survival will be computed
- Biomarker response [ Time Frame: Up to 4 years ]Proportion of patients with carcinoembryonic antigen (CEA) response with ≥ 50% decline from baseline (in patients with baseline level ≥ 3.2) post combination therapy with Tas-102 and 90Y radioembolization. Maximum percent change will be calculated. CEA level will only be followed for participants with elevated level (≥3.2) at baseline.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male or female, 18 years of age or older, and of any ethnic or racial group.
- Diagnosis of unresectable metastatic colorectal adenocarcinoma with liver-dominant bilobar disease. Diagnosis may be made by histo- or cyto-pathology, or by clinical and imaging criteria.
- Disease progression or intolerance to at least two prior Food and Drug Administration-approved therapeutic regimens.
- If extrahepatic disease is present, it must be asymptomatic.
- If a primary tumor is in place, it must be asymptomatic.
- Measurable target tumors using standard imaging techniques (RECIST v. 1.1 criteria).
- Tumor replacement < 50% of total liver volume.
- Current Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 through screening to first treatment on study.
- Completion of prior systemic therapy at least 14 days prior to enrollment.
- Able to understand informed consent.
At risk of hepatic or renal failure
- Serum creatinine > 1.5 mg/dl
- Serum bilirubin > 1.3 mg/ml
- Albumin < 2.0 g/dL
- Aspartate and/or alanine aminotransferase level > 5 times upper normal limit
- Any history of hepatic encephalopathy
- Cirrhosis or portal hypertension
- Clinically evident ascites (trace ascites on imaging is acceptable)
Contraindications to angiography and selective visceral catheterization
- Any bleeding diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents (e.g. closure device)
- Severe allergy or intolerance to contrast agents, narcotics, or sedatives that cannot be managed medically
- Symptomatic lung disease
- Prior therapy with Tas-102.
Contraindications to Tas-102
- Absolute neutrophil count < 1,500/μl
- Platelet count < 75,000/μl
- Allergy or intolerance to Tas-102
- Unresolved toxicity of greater than or equal to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 2 due to prior therapies.
Evidence of potential delivery of
- Greater than 30 Gy absorbed dose of radiation to the lungs during a single 90Y resin microsphere administration; or
- Cumulative delivery of radiation to the lungs > 50 Gy over multiple treatments.
- Evidence of any detectable Tc-99m macro aggregated albumin flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow.
- Previous radiation therapy to the lungs and/or to the upper abdomen
- Any prior arterial liver-directed therapy, including chemoembolization, bland embolization, and 90Y radioembolization
- Any intervention for, or compromise of the ampulla of Vater
- Active uncontrolled infection. Presence of latent or medication-controlled HIV and/or viral hepatitis is allowed.
Significant extrahepatic disease
- Symptomatic extrahepatic disease (including primary tumor, if unresected).
- Greater than 10 pulmonary nodules (each < 20 mm in diameter) or combined diameter of all pulmonary nodules > 15 cm.
- Peritoneal carcinomatosis
- Life expectancy less than 3 months
- Pregnant or lactating female
- In the investigator's judgment, any co-morbid disease or condition that would place the patient at undue risk and preclude safe use of radioembolization or Tas-102.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02602327
|United States, California|
|University of California San Francisco|
|San Francisco, California, United States, 94143|
|Principal Investigator:||Nicholas Fidelman, MD||University of California, San Francisco|
|Principal Investigator:||Katherine Van Loon, MD||University of California, San Francisco|
|Responsible Party:||University of California, San Francisco|
|Other Study ID Numbers:||
NCI-2017-01321 ( Registry Identifier: NCI Clinical Trials Reporting Program (CTRP) )
|First Posted:||November 11, 2015 Key Record Dates|
|Last Update Posted:||August 1, 2022|
|Last Verified:||July 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases